Trade: Will Integra Lifesciences (IART) beat quarterly earnings?

Market context

Integra Lifesciences will report first-quarter 2026 earnings on 5 May, with the market resolving based on whether non-GAAP EPS exceeds the Street consensus of $0.40. The current order book on Polymarket reflects a 100% implied probability for a beat, suggesting traders are pricing in minimal downside risk to the consensus figure. This extreme confidence warrants scrutiny, as consensus estimates for medical device manufacturers typically embed modest conservatism rather than aggressive assumptions.

Integra's historical earnings performance shows the company has beaten consensus in recent quarters, though the magnitude varies. Over the past two years, the company has demonstrated consistent execution in its neurosurgery and orthopaedic segments, which together represent the bulk of revenues. However, device companies face quarterly volatility from procedure volumes, reimbursement timing, and integration costs from acquisitions. The 100% probability on the order book suggests the market is discounting tail risks entirely—a positioning that leaves little room for execution misses or guidance revisions.

Key catalysts before the 5 May earnings date include any product recalls, regulatory setbacks, or unexpected commentary from management at industry conferences. Traders should monitor quarterly procedure volume trends and any changes to reimbursement rates for spinal and neuro products. The company's recent M&A activity and integration progress will also influence whether management can deliver against the consensus target. Any pre-earnings guidance updates or analyst downgrades would shift the probability materially from its current extreme level.

Resolution source

This market settles from the official outcome published at https://seekingalpha.com/. A proposer submits the final result to the UMA optimistic oracle on Polygon; the two-hour dispute window closes and payouts clear in USDC.

How to trade this market step by step

The mechanics for trading "Will Integra Lifesciences (IART) beat quarterly earnings?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.

1. Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
2. Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
3. Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
4. Size your position. If you stake 100 USDC at 100% YES, you'll receive shares that pay $100 if YES resolves true — a 0% gross return. If NO resolves, your shares are worth $0.
5. Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
6. Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.

How active is this market?

$3K in lifetime turnover and $0 of resting liquidity puts this market in the below the median by volume for iart contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.

The market has been open for under a month — fresh enough that information asymmetry remains a real factor.

Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.

Key terms

YES / NO share

A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.

CLOB

Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.

Liquidity

USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.

UMA optimistic oracle

The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.

Slippage

The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.

Conditional token

ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.

See the full prediction-market glossary →

Frequently asked questions

Risk and regulatory note

Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.

Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.

Related prediction markets

Explore more prediction market odds and trading opportunities on PolyGram:

• All iart prediction markets
• How prediction markets work
• Browse all prediction markets on PolyGram
• Top prediction market traders
• Back to PolyGram home